These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15868990)

  • 1. [Microvascular dysfunction as an explanation for the metabolic syndrome].
    Serné EH; de Jongh RT; Ijzerman RG; Stehouwer CD
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):866-70. PubMed ID: 15868990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microvascular dysfunction: causative role in the association between hypertension, insulin resistance and the metabolic syndrome?
    Serné EH; de Jongh RT; Eringa EC; Ijzerman RG; de Boer MP; Stehouwer CD
    Essays Biochem; 2006; 42():163-76. PubMed ID: 17144887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease?
    Krentz AJ; Clough G; Byrne CD
    J Vasc Res; 2009; 46(6):515-26. PubMed ID: 19571572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
    Hilgers KF; Mann JF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3389-91. PubMed ID: 18687734
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antihypertensive agents and the risk of new onset diabetes mellitus].
    Kuzmanić D; Laganović M; Dika Z; Kos J; Pećin I
    Lijec Vjesn; 2006; 128(11-12):336-41. PubMed ID: 17212194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic options for metabolic syndrome in obese patients].
    Carella AM; Conte M
    Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antihypertensive agents on the development of type 2 diabetes mellitus.
    Stump CS; Hamilton MT; Sowers JR
    Mayo Clin Proc; 2006 Jun; 81(6):796-806. PubMed ID: 16770980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metabolic syndrome: limited significance for clinical practice].
    Dekker JM; Diamant M; Nijpels G; Heine RJ
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):855-8. PubMed ID: 15868988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arterial hypertension and metabolic syndrome].
    Christ M; Klima T; Maisch B
    Herz; 2003 Dec; 28(8):674-85. PubMed ID: 14689101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global cardiometabolic risk profile in patients with hypertension: results from the Turkish arm of the pan-European GOOD survey.
    Kabakcı G; Aydın M; Demir I; Kırma C; Özerkan F
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):313-20. PubMed ID: 21200100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
    Deedwania PC; Schmieder R
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
    Kékes E
    Orv Hetil; 2008 Sep; 149(39):1827-37. PubMed ID: 18805771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.
    McInnes GT
    J Hum Hypertens; 2011 Jun; 25(6):343-5. PubMed ID: 21390054
    [No Abstract]   [Full Text] [Related]  

  • 20. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.